Jacqueline Garcia, MD, discusses results from a phase Ib study evaluating venetoclax and azacitidine in patients with treatment-naïve high-risk myelodysplastic syndromes.
Jacqueline Garcia, MD, discusses results from a phase Ib study evaluating venetoclax and azacitidine in patients with treatment-naïve high-risk myelodysplastic syndromes.